AKERS BIOSCIENCES, INC. (NASDAQ:AKER) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 25, 2018, the board of directors (the “Board”) of Akers Biosciences, Inc. (the “Company”) terminated Dr. Raymond F. Akers from his position as Executive Chairman of the Board and from each of his officer positions as Chief Scientific Director and Secretary of the Company. Dr. Raymond F. Akers continues as a member of the Board.
On April 25, 2018, the Board appointed Richard Carlyle Tarbox III, a current director of the Company as the interim Non-Executive Chairman of the Board, to hold that position until his successor is appointed in accordance with the Amendment to Restated By-laws of the Company, and to the position of Secretary of the Company. Mr. Tarbox accepted such appointments on April 25, 2018, and such appointments have become effective on such date.